EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cysteamine/Cystamine Exert Anti-Mycobacterium abscessus Activity Alone or in Combination with Amikacin

Ivana Palucci iD, Alessandro Salustri, Flavio De Maio iD, Maria Del Carmen Pereyra Boza, Francesco Paglione, Michela Sali, Luca Occhigrossi iD, Manuela D'Eletto, Federica Rossin iD, Delia Goletti iD, Maurizio Sanguinetti iD, Mauro Piacentini und 1 weitere

International Journal of Molecular Sciences · 07.01.2023 · 24 (2) · 1203

DOI: 10.3390/ijms24021203 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 07.01.2023. Verfasst von Ivana Palucci und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Sciences and Infectious Diseases, Fondazione Policlinico Universitario "A. Gemelli", 00168 Rome, Italy. Hauptthemen laut MEDLINE: Mycobacterium abscessus, Mycobacterium Infections, Nontuberculous. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: RICERCA FINALIZZATA 2018, Fondazione Fibrosi Cistica, National Institute for Infectious Diseases IRCCS 'Lazzaro Spallanzani'.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Host-directed therapies are emerging as a promising tool in the curing of difficult-to-treat infections, such as those caused by drug-resistant bacteria. In this study, we aim to test the potential activity of the FDA- and EMA-approved drugs cysteamine and cystamine against Mycobacterium abscessus. In human macrophages (differentiated THP-1 cells), these drugs restricted M. abscessus growth similar to that achieved by amikacin. Here, we use the human ex vivo granuloma-like structures (GLS) model of infection with the M. abscessus rough (MAB-R) and smooth (MAB-S) variants to study the activity of new therapies against M. abscessus. We demonstrate that cysteamine and cystamine show a decrease in the number of total GLSs per well in the MAB-S and MAB-R infected human peripheral blood mononuclear cells (PBMCs). Furthermore, combined administration of cysteamine or cystamine with amikacin resulted in enhanced activity against the two M. abscessus morpho variants compared to treatment with amikacin only. Treatment with cysteamine and cystamine was more effective in reducing GLS size and bacterial load during MAB-S infection compared with MAB-R infection. Moreover, treatment with these two drugs drastically quenched the exuberant proinflammatory response triggered by the MAB-R variant. These findings showing the activity of cysteamine and cystamine against the R and S M. abscessus morphotypes support the use of these drugs as novel host-directed therapies against M. abscessus infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium abscessusMycobacterium Infections, NontuberculousHumansAmikacinAnti-Bacterial AgentsCysteamineCystamineLeukocytes, MononuclearMicrobial Sensitivity Tests

Stichwörter der Autor:innen

Mycobacterium abscessuscystaminecysteaminehost-directed therapiestransglutaminase-2

Substanzen

AmikacinAnti-Bacterial AgentsCysteamineCystamine

Autor:innen und Institutionen

  • Department of Laboratory Sciences and Infectious Diseases, Fondazione Policlinico Universitario "A. Gemelli", 00168 Rome, Italy.
  • Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie-Sezione di Microbiologia, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
  • Dipartimento di Biologia, Università degli Studi di Roma "Tor Vergata", 00173 Rome, Italy.
  • Department of Epidemiology and Preclinical Research, National Institute for Infectious Diseases Translational Research Unit, IRCCS 'Lazzaro Spallanzani', 00149 Rome, Italy.
  • Mater Olbia Hospital, 07026 Olbia, Italy.

ORCID-Profile: Ivana Palucci, Flavio De Maio, Luca Occhigrossi, Federica Rossin, Delia Goletti, Maurizio Sanguinetti

Förderung

  • RICERCA FINALIZZATA 2018
  • Fondazione Fibrosi Cistica
  • National Institute for Infectious Diseases IRCCS 'Lazzaro Spallanzani'
  • Italian Ministry of Health
  • National Institute for Infectious Diseases IRCCS ‘Lazzaro Spallanzani’
  • Italian Ministry of Health, Ricerca Corrente

Zitieren

APA

Palucci, I., Salustri, A., De Maio, F., Pereyra Boza, M. D. C., Paglione, F., Sali, M., Occhigrossi, L., D'Eletto, M., Rossin, F., Goletti, D., Sanguinetti, M., Piacentini, M., & Delogu, G. (2023). Cysteamine/Cystamine Exert Anti-Mycobacterium abscessus Activity Alone or in Combination with Amikacin. International Journal of Molecular Sciences, 24(2), 1203. https://doi.org/10.3390/ijms24021203

Vancouver

Palucci I, Salustri A, De Maio F, Pereyra Boza MDC, Paglione F, Sali M, et al. Cysteamine/Cystamine Exert Anti-Mycobacterium abscessus Activity Alone or in Combination with Amikacin. International Journal of Molecular Sciences. 2023;24(2):1203. doi:10.3390/ijms24021203

BibTeX
@article{Palucci2023,
  author = {Palucci, Ivana and Salustri, Alessandro and De Maio, Flavio and Pereyra Boza, Maria Del Carmen and Paglione, Francesco and Sali, Michela and Occhigrossi, Luca and D'Eletto, Manuela and Rossin, Federica and Goletti, Delia and Sanguinetti, Maurizio and Piacentini, Mauro and Delogu, Giovanni},
  title = {Cysteamine/Cystamine Exert Anti-Mycobacterium abscessus Activity Alone or in Combination with Amikacin},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {2},
  pages = {1203},
  doi = {10.3390/ijms24021203}
}
Kostenlos starten →